This was achieved by using CRISPR-Cas9 to induce the PTPN2/22 SNPs in the genomic DNA of Jurkat T-cells and measuring their effect on PTPN2/22 gene expression, T-cell proliferation, pro-inflammatory cytokine secretion, and T-cell activation, which are all reportedly effected in CD and RA patients [5,10]. This evidence concerns the gene PTPN2 and rheumatoid arthritis.